Abstract
For an in vitro mutant of Streptococcus pneumoniae selected on moxifloxacin four- to eightfold-increased MICs of new fluoroquinolones, only a twofold-increased MIC of ciprofloxacin, and a twofold-decreased MIC of novobiocin were observed. This phenotype was conferred by two mutations: Ser81Phe in GyrA and a novel undescribed His103Tyr mutation in ParE, outside the quinolone resistance-determining region, in the putative ATP-binding site of topoisomerase IV.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenosine Triphosphate / metabolism
-
Amino Acid Sequence
-
Anti-Infective Agents / pharmacology*
-
Bacterial Proteins / genetics*
-
Binding Sites
-
DNA Topoisomerase IV
-
DNA Topoisomerases, Type II / metabolism
-
DNA-Binding Proteins / genetics*
-
Drug Resistance, Microbial / genetics
-
Fluoroquinolones
-
Humans
-
Microbial Sensitivity Tests
-
Molecular Sequence Data
-
Mutation
-
Phenotype
-
Pneumococcal Infections / microbiology
-
Sequence Homology, Amino Acid
-
Streptococcus pneumoniae / drug effects*
-
Streptococcus pneumoniae / genetics
Substances
-
Anti-Infective Agents
-
Bacterial Proteins
-
DNA-Binding Proteins
-
Fluoroquinolones
-
Adenosine Triphosphate
-
DNA Topoisomerase IV
-
DNA Topoisomerases, Type II